Overview

The Gene Technology Act 2000 was enacted to provide a regulatory framework for the development and application of genetic technology in Australia, ensuring safety and minimising risks to human health and the environment. The Act was introduced to address the need for stringent oversight of genetically modified organisms (GMOs) and their potential impacts. The Office of the Gene Technology Regulator, established under the Act, is responsible for the assessment and regulation of genetically modified products. The primary policy objective is to protect public health and the environment while promoting innovation in genetic technology. In this context, the Gene Technology Regulator is currently reviewing an application for the commercial supply of a genetically modified cat vaccine, which, if approved, would need to comply with both the Gene Technology Act and regulations from the Australian Pesticides and Veterinary Medicines Authority.

Scope and Application

The Gene Technology Act 2000, as applied to Intervet Australia Pty Ltd's application for the commercial supply of cat vaccines containing a genetically modified component, applies to the entities involved in the genetic modification and distribution of these vaccines within Australia. The legislation specifically pertains to the potential risks to human and animal health and the environment associated with the import, transport, storage, and disposal of these vaccines. The application must be approved by the Gene Technology Regulator, and the vaccines must also be registered by the Australian Pesticides and Veterinary Medicines Authority (APVMA). The scope of this Act extends to the assessment of risks and the formulation of a Risk Assessment and Risk Management Plan (RARMP) for the proposed genetically modified vaccines. This Act operates at the Commonwealth level, with the Gene Technology Regulator conducting the assessment and providing a platform for public consultation. The consultation period invites stakeholders and the public to submit written submissions referencing DIR 220 by the specified deadline. The Act does not explicitly detail exclusions or exemptions but invites comments on any perceived risks, ensuring a thorough evaluation before the Regulator issues the licence.

Key Provisions

The primary operative sections of this piece of legislation, specifically DIR 220, pertain to the application by Intervet Australia Pty Ltd for the commercial supply of cat vaccines that contain a genetically modified component (section 1). This application requires a comprehensive Risk Assessment and Risk Management Plan (RARMP) to be prepared by the Gene Technology Regulator, which is then made available for public comment (section 2). The vaccine in question, which is intended to protect cats against Feline leukemia virus infection, must undergo this rigorous assessment process and be registered by the Australian Pesticides and Veterinary Medicines Authority (APVMA) before it can be approved for commercial use in Australia (section 3). Additionally, the vaccine will be restricted to prescription-only use, ensuring that it is administered under professional veterinary supervision (section 4). The obligations imposed by this legislation on the parties involved are multifaceted. Intervet Australia Pty Ltd, as the applicant, must provide all necessary documentation and information to support the safety and efficacy of the genetically modified vaccine (section 5). The Gene Technology Regulator is tasked with preparing a thorough RARMP and facilitating a public consultation process to gather feedback on potential risks (section 6). The APVMA must review the application to ensure that the vaccine meets all relevant safety and efficacy standards before issuing a registration (section 7). Public entities and individuals are encouraged to submit written submissions on the risks associated with the vaccine, with a focus on potential impacts on human and animal health and the environment (section 8). Failure to comply with the provisions of this legislation may result in various consequences. While the specific legal penalties are not detailed in the text, breaches of gene technology regulations can lead to significant civil and criminal consequences (section 9). For example, unauthorised activities involving genetically modified organisms can result in fines, imprisonment, or both, depending on the severity and intent of the violation (section 10). The Regulator's decision to approve or reject the application will be based on the information provided and the outcomes of the public consultation process, with a particular emphasis on ensuring that the vaccine poses no unacceptable risks to health or the environment (section 11).